Patent 10987410 was granted and assigned to Synthetic Biologics, Inc. on April, 2021 by the United States Patent and Trademark Office.
The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.